Defining the anti-tumour efficacy of CDK4/6 inhibitors in combination with chemotherapy and possible mechanisms of resistance in murine and patient derived xenograft models of Medulloblastoma (2018-2021)

Medulloblastoma (MB) is a leading cause of cancer-related mortality and morbidity in children. Few effective therapies are available for patients with high-risk disease or tumours that recur following standard-of-care therapy and thus, these patients have a poor prognosis. Based on this, we focused on identifying novel MB targeted therapies for MB. Using a functional genomics and bioinformatics approach in a MB mouse model, gene networks dysregulated in all MB subgroups have been identified. A druggable genome analysis of these networks defined potential new therapeutics, validating CDK4/6 inhibition as a possible therapeutic strategy for multiple subgroups of MB.